Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

105.01 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	385
Open	105.01
Bid (Size)	85.00 (200)
Ask (Size)	167.72 (100)
Prev. Close	105.01
Today's Range	105.01 - 105.01
52wk Range	45.91 - 122.20
Shares Outstanding	66,684,077
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The Great Divergence: Why Big Tech Holds the Line While Logistics and Biotech Face a 2026 Reckoning

December 30, 2025

As the curtain closes on 2025, the financial landscape presents a tale of two markets. While the S&P 500 (NYSEARCA: SPY) hovers near the historic 7,000-point milestone, fueled by a 19% year-to-date...

Via MarketMinute

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three...

Via MarketMinute

Performance

YTD	N/A	N/A
1 Month	+0.4%	+0.4%
3 Month	+7.3%	+7.3%
6 Month	+58.2%	+58.2%
1 Year	+78.1%	+78.1%

More News

Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder ↗

December 11, 2025

Via Stocktwits

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Rhythm Pharmaceuticals's Earnings: A Preview ↗

November 03, 2025

Via Benzinga

The market is filled with gapping stocks in Thursday's session. ↗

December 11, 2025

Via Chartmill

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

December 11, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Stay updated with the stocks that are on the move in today's after-hours session. ↗

December 10, 2025

Via Chartmill

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

December 10, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

These stocks are moving in today's after hours session ↗

November 11, 2025

Via Chartmill

Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025

November 10, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million ↗

November 08, 2025

Via The Motley Fool

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

November 07, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

November 05, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals (NASDAQ:RYTM) Reports Mixed Q3 2025 Results ↗

November 04, 2025

Via Chartmill

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

November 04, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Curious about the stocks that are showing activity after the closing bell on Monday? ↗

October 27, 2025

Via Chartmill

Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

October 21, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

2 Under-the-Radar Stocks That Could Soar ↗

September 21, 2025

Via The Motley Fool

Peering Into Rhythm Pharmaceuticals's Recent Short Interest ↗

September 11, 2025

Via Benzinga

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

August 27, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

August 20, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

12 Analysts Have This To Say About Rhythm Pharmaceuticals ↗

August 06, 2025

Via Benzinga

Rhythm (RYTM) Q2 Revenue Jumps 67% ↗

August 05, 2025

Via The Motley Fool

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Reports Mixed Q2 2025 Earnings: Revenue Beat Overshadowed by Wider Losses ↗

August 05, 2025

Via Chartmill

Frequently Asked Questions

Is Rhythm Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Rhythm Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Rhythm Pharmaceuticals, Inc. - Common Stock trade on?

Rhythm Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock is RYTM on the Nasdaq Stock Market

What is the current price of Rhythm Pharmaceuticals, Inc. - Common Stock?

The current price of Rhythm Pharmaceuticals, Inc. - Common Stock is 105.01

When was Rhythm Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Rhythm Pharmaceuticals, Inc. - Common Stock was at 01/02/26 04:00 PM ET

What is the market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock is 7.00B

How many shares of Rhythm Pharmaceuticals, Inc. - Common Stock are outstanding?

Rhythm Pharmaceuticals, Inc. - Common Stock has 7B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.